“If we knew what it was we were doing, it would not be called research, would it?” – Albert Einstein
Recently there was a study about treating those MM patients that were historically in the “wait and see” mode. As you can imagine folks were a bit rattled (an understatement). Kind of like how we feel when someone says SCT shows better lifespan, or Tandem wins, or delayed SCT shows same results, etc. We can get all whigged out about whatever choice we have made. (Which BTW, I recommend not doing that. Don’t second guess, don’t be dismayed. You made the right decision for you at the time bringing in all the factors that were important to you with the information then.)
Ok. So The Myeloma Beacon being ever vigilant and having a continuing uncanny perception on how their readership might be feeling with certain news, did an article today with a Dr. Ola Landgren, a MM researcher at NIH that specializes in this particular group of MM patient presentation.
A recent commenter on my blog mentioned that he sees Dr. Landgren. I had not heard of him, but then we are not MGUS or Smoldering, so I didn’t beat myself up too much about it. It was kind of cool to see his name so quickly after this mention. Between him studying those not yet symptomatic and Dr. Bart Barlogie (et al) studying those who are demonstrating high resistance to drugs, both looking for the genetic markers, I think we got it covered!
Margaret’s response to the Beacon article here! I gladly defer to her on this issue as she has been blogging as an MM patient in this category for a very long time.